Inventiva's Lanifibranor Shows Promise in Portal Hypertension Study

Inventiva has published results from a preclinical study in "Biomedicine & Pharmacotherapy" revealing the potential of lanifibranor in improving portal hypertension (PH). The study, conducted in collaboration with Ghent University Hospital, examined lanifibranor's effects on PH across different mouse models.

The findings indicate that lanifibranor can decrease portal pressure by enhancing liver sinusoidal endothelial cell dysfunction and reducing fibrosis. Additionally, the study highlighted lanifibranor's ability to influence the splanchnic vasculature through anti-angiogenetic effects.

Lanifibranor's potential as a therapeutic candidate to address PH-related complications in liver diseases is notable. Extensive structural changes in mesenteric vascular architecture were reversed following treatment, showcasing lanifibranor's efficacy in tackling both fibrotic and non-fibrotic PH models.